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A B S T R A C T
Background. Bone impairment is a poorly described complication of nephropathic cystinosis (NC). The objectives of this study were to evaluate in vitro effects of cystinosin (CTNS) mutations on bone resorption and of cysteamine treatment on bone cells [namely human osteoclasts (OCs) and murine osteoblasts]. Methods. Human OCs were differentiated from peripheral blood mononuclear cells (PBMCs) of patients and healthy donors (HDs). Cells were treated with increasing doses of cysteamine in PBMCs or on mature OCs to evaluate its impact on differentiation and resorption, respectively. Similarly, cysteamine-treated osteoblasts derived from murine mesenchymal stem cells were assessed for differentiation and activity with toxicity and proliferation assays. Results. CTNS was expressed in human OCs derived from HDs; its expression was regulated during monocyte colonystimulating factor-and receptor activator of nuclear factor-jBdependent osteoclastogenesis and required for efficient bone resorption. Cysteamine had no impact on osteoclastogenesis but inhibited in vitro HD osteoclastic resorption; however, NC OC-mediated bone resorption was impaired only at high doses. Only low concentrations of cysteamine (50 lM) stimulated osteoblastic differentiation and maturation, while this effect was no longer observed at higher concentrations (200 mM). Conclusion. CTNS is required for proper osteoclastic activity. In vitro low doses of cysteamine have beneficial antiresorptive effects on healthy human-derived OCs and may partly correct the CTNS-induced osteoclastic dysfunction in patients with NC. Moreover, in vitro low doses of cysteamine also stimulate osteoblastic differentiation and mineralization, with an inhibitory effect at higher doses, likely explaining, at least partly, the bone toxicity observed in patients receiving high doses of cysteamine.
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I N T R O D U C T I O N
Nephropathic cystinosis (NC; 1/200 000 live births) is a rare autosomal recessive lysosomal storage disease characterized by a deficiency of the cystine lysosomal transport protein [i.e. cystinosin (CTNS) encoded by the CTNS gene], resulting in systemic accumulation of cystine crystals, thus leading to tissue damage. Patients suffer early from complete proximal tubulopathy; the natural evolution is a progressive chronic interstitial nephritis leading to end-stage renal disease (ESRD) within the first decade of life [1] . The use of cysteamine therapy since the 1980s has postponed ESRD and extrarenal morbidities to the second or third decade of life, at least in developed countries [2] .
As patients receive cysteamine and improve survival [1] , bone impairment was recently described to be a complication of NC, occurring during teenage or early adulthood [3] [4] [5] [6] ; even though the exact underlying pathophysiology is unclear, six hypotheses are discussed: copper deficiency [7] , consequences of hypophosphatemic rickets together with iatrogenic effects of its supportive treatment, cysteamine toxicity [8] , abnormal thyroid metabolism, chronic hypoparathyroidism and/or direct bone effect of the CTNS mutation [9] .
Significant bone impairment observed in NC patients is partly due to bone formation defects [3] [4] [5] . However, bone resorption precedes bone formation, contributing equally to the sustaining of bone mass integrity, and should also be considered in the context of cystinosis. Osteoclasts mediate bone degradation by forming a sealing zone, which defines a confined lacuna where the ruffle border secretes protons and proteases to acidify and degrade the bone matrix. Although the resorption process highly depends on lysosomal activity and acidification, CTNS involvement has been scarcely studied in osteoclasts (OCs) [10] .
Our working hypotheses were that altered OC differentiation and mediated resorption may also contribute to bone impairment and that cysteamine treatment may modify this interplay. The objectives of the present study were therefore to assess the impact of CTNS mutations on OC intrinsic differentiation and function and to evaluate the effect of cysteamine in vitro on bone cells [namely human OCs derived from peripheral blood mononuclear cells (PBMCs) and murine osteoblasts derived from mesenchymal stem cells (MSCs)].
M A T E R I A L S A N D M E T H O D S

Primary OC culture
Monocytes were purified from 15 mL of peripheral blood. After collection, blood was loaded on a lymphocyte separation medium density gradient (Eurobio, Courtaboeuf, France) to purify mononuclear cells. Monocytes were then plated in 96-well plates at a density of 105 cells/well and cultured in minimum essential medium a (Gibco Life Technologies, Grand Island, NY, USA) supplemented with 2 mM L-glutamine (Gibco Life Technologies), 1% penicillin/streptomycin (Gibco Life Technologies) and 10% foetal bovine serum (FBS; Dominique Dutscher, Brumath, France) as previously described [11] . OCs were obtained by incubating monocytes with 20 ng/mL monocyte colony-stimulating factor (M-CSF; PeproTech, Rocky Hill, NJ, USA) and 40 ng/mL of receptor activator of nuclear factor j-B ligand (RANKL; PeproTech) from Day 1 to Day 5. All PBMCs were treated with a combination of RANKL and M-CSF in order to differentiate them into functioning OCs. From the second day on, osteoclastic precursors were treated with increasing doses of cysteamine (control 50-200 lM) during differentiation.
OC functional assays
At the end of the osteoclastic differentiation protocol (Day 5), the cells were harvested for real-time polymerase chain reaction (PCR) analysis or were fixed with 4% paraformaldehyde (PFA) and stained with a leucocyte acid phosphatase (TRAP) staining kit according to the manufacturer's instructions (Sigma-Aldrich, St Louis, MO, USA). Cells that stained positive (>3 nuclei) were then counted. OC activity was assessed by culturing cells on plates coated with a synthetic inorganic bone mimetic matrix (Osteoassay, Corning, Illkirch, France) after 5 days of differentiation without treatment. Increasing doses of cysteamine (control 50-200 lM) were added at Day 2 and maintained until the end. At Day 7, to measure the surface of the resorbed matrix, OCs were washed with distilled water and the matrix was stained with a 5% (wt/vol) silver nitrate solution; the pits produced by OCs appeared as white spots under a light microscope: their surfaces were quantified by ImageJ software.
Isolation and culture of murine MSC-derived osteoblasts
Bone marrow was flushed out of mice long bones, counted, plated at a density of 20Â10 6 cells/100-mm diameter flask in MEM supplemented with 15% FBS and expanded for 1 week, supplemented with 2 mM L-glutamine and 1% penicillin/streptomycin (all reagents, Gibco Life Technologies). MSCs were harvested, after reaching 80% confluence, using cell dissociation solution (Sigma-Aldrich) and were seeded in 12-well plates at a density of 2 Â10 5 cells/well; osteogenic media was then added 2 days later [50 mg/mL L-ascorbic and 10 mM of b-glycerol phosphate (Sigma-Aldrich) supplemented with 10% FBS]. Subsequently, MSCs were treated with increasing doses of cysteamine (Sigma-Aldrich; control, 10, 50, 100 and 200 lM) during the differentiation assay. Treatment with cysteamine was added the second day of differentiation and maintained until Day 21. After 3 weeks of culture, cells were washed with phosphate-buffered saline, fixed with 4% PFA and analysed for osteogenic differentiation and DNA content (see below). Alkaline phosphatase (ALP) activity was assessed according to the manufacturer's procedures, whereas calcium deposition was visualized using von Kossa (VK) staining through the use of silver nitrate (both from Sigma-Aldrich). ALP and VK positivity were quantified by ImageJ software.
Reverse transcription and real-time quantitative PCR
RNA isolation and purification were obtained from Trizol Cell Extracts in accordance with the manufacturer's instruction (Life Technologies and Ambion); cDNA synthesis was carried out with the iScript Reverse Transcription for real-time quantitative PCR (qPCR) (Bio-Rad Laboratories, Marnes-la-Coquette, France). qPCRs were performed using iTaq Universal SYBR Green Supermix and amplification run on a CFX connect RealTime System (Bio-Rad Laboratories). Systematic controls were generated without iScript and amplified and qPCR was carried out in duplicate for each data point. Primers for the amplification of osteogenic or osteoclastic markers were the following: mOCN (osteocalcin), mCOL1 (collagen type 1), mOSX (osterix) and hcathepsin K. Expression of these genes was quantified and normalized to corresponding RNA L32 values and expressed as relative expression using the 2 ÀDDC t method.
Cysteamine toxicity and effect on proliferation of osteoblasts Proliferation 5-bromo-2 0 -deoxyuridine (BrdU) test. Cysteamine was tested for its impact on osteoblastic proliferation and 25 000 cells were seeded into each well of a 96-well plate in growth medium and incubated under standard conditions for 2 days, adding L-ascorbic and b-glycerol phosphate after the first 24 h. After starving for 48 h, cells were incubated with increasing doses of cysteamine (10, 50, 100 and 200 mM) in culture medium. After a 24-, 48-and 72-h incubation period, BrdU (100 lM) was added to each well and cells were allowed to grow for an additional 120 min. The incorporation of BrdU into DNA was measured according to the supplier's instructions with the Cell Proliferation enzyme-linked immunosorbent assay (chemiluminescence, Roche Diagnostics, Mannheim, Germany). Cells not subjected to cysteamine served as a negative control (NC). All measurements were run in quadruplicate and proliferation values were calculated relative to the NC, whose viability was set to 100%. The reading was carried out through the Microplate Manager 5.2 (Bio-Rad) with a wavelength of 450 nm and the results expressed in optical densitometry.
Lactate dehydrogenase (LDH) assay. To prepare samples for the LDH assay, the same protocol used for isolation and culture of MSC-derived cells was followed; 150 mL of culture medium was recovered and analysed on Days 0, 2, 7, 9 and 14 of protocol. LDH activity was determined using commercial kits (ABBOTT Diagnostics, Ref. 2P56, Rungis, France) on an Architect C16000 auto-analyser (ABBOTT Diagnostics).
Statistical analyses
Statistical analyses performed using Prism 5.03 (GraphPad Software, La Jolla, CA, USA). Two-group analysis was performed using t-tests for parametric data and the MannWhitney U-test for non-parametric distributions. In all cases, P < 0.05 was considered significant. Values were expressed as mean 6 standard error of the mean (SEM). For the part involving human circulating monocytes differentiated into functional OCs in vitro, the study was approved by the local institutional review board (Comité de Protection des Personnes Lyon Sud Est II, 9 July 2016 session). Written informed consent was obtained from all patients and controls (and parents in case of paediatric subjects).
R E S U L T S Cystinosis increases osteoclastogenesis but decreases bone resorption activity of OCs derived from human PBMCs
As shown in Figure 1A , CTNS is expressed in human OCs derived from healthy donors (HDs); its expression is regulated along with M-CSF and RANKL-dependent osteoclastogenesis: indeed, a peak of CTNS expression was observed at Day 6 in mature OCs following the same pattern of cathepsin K transcripts. We therefore evaluated OC differentiation of PBMCs from patients and healthy controls using the number of TRAPpositive multinucleated cells at the end of the differentiation process with M-CSF and RANKL. The results are summarized in Table 1 . First, when osteoclastogenesis was examined in basic conditions without any treatment, an increase of multinucleated TRAP-positive cells was observed in patients in comparison with controls, despite the fact that they were generated from the same number of monocyte progenitors ( Figure 1B and C). These findings clearly indicate that cystinosis favoured osteoclastogenesis and that cystinosis mononuclear progenitors are more prone to generate OCs than controls.
In OCs derived from human PBMCs, cysteamine has no significant effect on differentiation but inhibits bone resorption activity Cysteamine had no effect on osteoclastic differentiation whatever the origin of the donors and the doses tested ( Figure  1B ). We therefore evaluated the resorption capacity of these OCs obtained from patients and controls with and without cysteamine exposure. In contrast to what we observed for differentiation, in vitro bone resorption (as assessed by the total bone surface resorbed or the resorption index) was clearly decreased in OCs from patients when compared with controls; similarly, we also found that cathepsin K transcript levels were decreased in patients compared with controls ( Figure  2A ). However, when examining the resorptive activity of cysteamine-treated OCs both in controls and patients, there was a beneficial antiresorptive effect; indeed, in controls, a 50% inhibition of the resorption activity was observed with 50 mM, although for NC patients the impairment of the OC activity was detectable and significant only at 200 mM of cysteamine (Table 1 and Figure 2B and C). Because of technical difficulties to obtain enough cells, it was unfortunately not possible to evaluate resorption with 50 mM in all subjects.
Low doses of cysteamine stimulate osteoblastic differentiation and mineralization, with an inhibitory effect at higher doses
To assess the ability of murine MSCs to differentiate as osteoblasts in the presence of similar cysteamine treatment as above, we monitored the expression level of early, mid-and late osteoblast-specific markers by real-time PCR, as illustrated in Figure 3 , including mOSX (osterix; Figure 3A ), mCOL1 (collagen type 1; Figure 3B ) and mOCN (osteocalcin; Figure 3C ). All markers were significantly upregulated on Day 21 in the group treated with 50 mM of cysteamine, however, they were down-regulated in the groups treated with high doses of cysteamine (namely 100/or 200 mM).
In order to further investigate the impact of cysteamine treatment on MSC-derived osteoblast function, their ability to mineralize matrix and to express ALP, VK and ALP stainings were performed at the end of the differentiation process. As illustrated for the VK staining ( Figure 3D ), significant increased mineralization in the group treated with 50 mM of cysteamine was observed. The BrdU labelling showed a significantly lower cell proliferation in the 200-mM group on Day 3 ( Figure 3E) ; a cytotoxic effect of cysteamine was ruled out since no increased LDH levels were found between groups ( Figure 3F ). ALP staining showed no significant differences between groups (ranging from 60 to 75% of ALP-positive cells per well), thus suggesting that the difference in proliferation observed at the early stages of the differentiation was no longer found at the endpoint of the experiment (namely the end of the differentiation process) ( Figure 3F ). This last observation supports the statement that there is no toxicity observed with cysteamine on primary osteoblast culture.
D I S C U S S I O N
Bone impairment in NC has a potential impact on quality of life and should be known by physicians. However, its pathophysiology remains unclear and this study is the first to provide new insights into the underlying mechanisms. First, CTNS is required for proper osteoclastic activity, suggesting an involvement of bone resorption in the outcome of cystinosis-derived bone lesions. In vitro low doses of cysteamine have beneficial antiresorptive effects only on healthy human-derived OCs and thus may partly correct the CTNS-induced osteoclastic dysfunction in patients with NC. Second, in vitro low doses of cysteamine stimulate osteoblastic differentiation and mineralization, with an inhibitory effect at higher doses, likely explaining, at least partly, the bone toxicity observed in patients receiving high doses of cysteamine.
In animal models, invalidation of the CTNS gene is not associated with either renal phosphate wasting or with renal failure, but causes severe osteopenia and growth retardation, thus raising the hypothesis of a specific underlying bone defect in cystinosis [9] . CTNS mutations also affect human osteoblast differentiation and function [12] . In the present study we show that CTNS gene expression is regulated during human osteoclastogenesis, under the control of M-CSF and RANKL, the two major cytokines driving OC differentiation and function. We also provide evidence that CTNS is necessary for proper bone resorption mediated by human OCs: OCs derived from patients display intrinsic altered differentiation and restrained resorption activity. Surprisingly, monocytes isolated from patients are more prone to generate multinucleated OCs, as if functional CTNS is a tuner of OC differentiation. Conversely, mature OCs from patients display a decreased resorption index even though they are not devoid of resorptive activity. We may then speculate that bones of NC patients have more OCs that are less active compared with those of healthy volunteers: in that setting, we previously reported extended and unusual areas of osteoclastogenesis in the patients who underwent bone biopsies [5] . In addition to the formation defects observed in patients, the altered balance of OC number and defective OC function may contribute to the specific bone defect in NC. This is not unexpected since lysosomes, vesicular trafficking and exocytosis are essential and tightly regulated in mature OCs in order to achieve efficient resorption [13] . Among human lysosomal storage diseases, some have been reported to induce a bone phenotype secondary to gene mutations involved in both lysosomal metabolism and in OCs, all of them leading to an osteopetrotic/ sclerotic bone phenotype with increased bone mineral density due to impaired OC-mediated resorption [10] . However, none of these lysosomal storage diseases target both bone formation and resorption, as cystinosis does, affecting both OC and osteoblast biology.
Cysteamine is an amino-thiol and an intercaling agent; it induces a disulphide exchange and a connection of cysteine to cysteamine, thus allowing lysosomal clearance and transport of this complex. The use of cysteamine has dramatically improved the long-term prognosis of cystinosis, but cysteamine toxicity (notably bony, cutaneous, vascular, neurological and muscular side effects) has nevertheless been discussed, occurring in cases of cysteamine overdose, affecting 1.5% of treated patients and improving with decreased daily doses of cysteamine [8] .
In bone, osteoblastic abnormalities can be reverted after cysteamine treatment, demonstrating beneficial effects of cysteamine on osteoblastic cells [12] . In our bone cell study we have used the range of cysteamine doses reported by published experimental studies in osteoblasts and fibroblasts [12, 14] . Murine MSCs differentiated into osteoblastic cells were submitted to cysteamine treatment. In vitro low doses of cysteamine stimulated osteoblastic differentiation and mineralization, providing evidence for a rather 'osteogenic' effect of cysteamine, while osteoclastic resorption was inhibited in HDs. These observations could lead to the conclusion that overall cysteamine has a beneficial dual effect on bone cells, restoring bone formation and inhibiting bone resorption. However, it is interesting to note that a 'resistance' to cysteamine appears in resorbing OCs from patients, whereas the inhibitory effect on bone resorption is already observed with 'low doses' of cysteamine in cells differentiated from HDs.
Lastly, using high doses of cysteamine in murine osteoblasts led to decreased differentiation and mineralization, because of decreased proliferation (and not cytotoxicity). These data correspond to the bone phenotype observed in patients with Cysteamine effects on murine MSCs/osteoblasts. To assess the ability of murine MSCs to differentiate as osteoblasts in the presence of cysteamine, we monitored the expression level of early, mid-and late osteoblast-specific markers by real-time PCR, including mOSX (osterix; A), mCOL1 (collagen type 1; B) and mOCN (osteocalcin; C), on Days 0, 7, 14 and 21 after cysteamine treatment and induction of osteogenic differentiation. Both markers were significantly upregulated on Day 21 in the group treated with 50 mM of cysteamine; however, they were downregulated in the groups treated with high doses of cysteamine (namely 100 or 200 mM). In order to investigate the impact of cysteamine treatment on MSCderived osteoblast function, their ability to mineralize matrix and to express ALP, VK and ALP stainings were performed at the end of the differentiation process. As illustrated for the VK staining (D), significant increased mineralization in the group treated with 50 mM of cysteamine was observed. Similar (albeit non-significant) results were obtained with the ALP staining. The luminescence captured from the BrdU-positive cells on Days 0, 1, 2 and 3 of treatment with cysteamine was expressed as optical density (OD) so as to evaluate cellular proliferation, showing a significantly lower cell proliferation in the 200-mM group on Day 3 (*P<0.05; E). To rule out a potential cytotoxic effect of cysteamine, LDH levels were measured in the medium: the graph represents the mean LDH values of three measurements on Days 0, 2, 7, 9 and 14 after cysteamine treatment.
No increased LDH levels were found between groups. Representative micrographs of ALP staining of osteoblast endpoint cultures used for LDH measurements are shown (F). Values are presented as mean 6 SEM. *P<0.05 and ***P<0.001 compared with untreated group.
cysteamine toxicity [8] and are the first to try to explain these clinical observations, but without providing the exact mechanistic profile. Indeed, these data suggest a shift from a favourable balance between inhibited resorption and stimulated osteoblastic mineralization using low doses of cysteamine towards an imbalance between inhibited resorption and decreased mineralization (thus favouring resorption and consequently inducing clinical bone symptoms) when using higher doses of cysteamine. In this specific setting of cystinosis, the distinction between bone lesions due to chronic kidney disease, renal osteodystrophy and therapies on the one hand and bone lesions due to cystinosis itself (whatever the exact underlying pathophysiology) or to secondary endocrine complications (e.g. hypothyroidism or hypogonadism) on the other hand remain challenging in clinical practice. However, we believe that our data in these cellular models provide interesting data on the dual effects of cysteamine on bone cells and may explain, at least partly, the bone toxicity observed in patients receiving high doses of cysteamine. In the future, the management of patients may rely on cysteamine through levels, but this hypothesis deserves more study. The evaluation of in vitro OC biology directly from patients' cells is a new promising technique, allowing us to evaluate OC biology with only 15 mL of circulating blood (instead of 250 mL previously) [11] . It opens promising perspectives, and despite the fact that it is a time-consuming procedure, we were able to perform the study in seven patients and seven controls with consistent results on resorption activity, thus allowing us to conclude a partial inhibitory effect of cysteamine on patient bone resorption as opposed to HDs.
In conclusion, bone impairment is a reality in teenagers and young adults with NC. Even though its pathophysiology remains largely unknown, we showed that CTNS is regulated during osteoclastogenesis and involved in bone-mediated resorption. From our study it appears that cysteamine treatment may have dual effects on bone cells. A better understanding of the underlying mechanisms of cysteamine activity in OCs and osteoblasts may improve the clinical management of patients with NC.
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